

Cite this: *Chem. Sci.*, 2022, 13, 2324

All publication charges for this article have been paid for by the Royal Society of Chemistry

# A highly selective and sensitive chemiluminescent probe for leucine aminopeptidase detection *in vitro*, *in vivo* and in human liver cancer tissue†

Baoqu Wang,<sup>‡a</sup> Zhenzhou Chen,<sup>‡a</sup> Xiaohong Cen,<sup>‡a</sup> Yuqing Liang,<sup>a</sup> Liyi Tan,<sup>a</sup> En Liang,<sup>a</sup> Lu Zheng,<sup>a</sup> Yanjun Zheng,<sup>a</sup> Zhikun Zhan<sup>a</sup> and Kui Cheng<sup>ib\*ab</sup>

Leucine aminopeptidase (LAP) is involved in tumor cell proliferation, invasion, and angiogenesis, and is a well-known tumor marker. In recent years, chemiluminescence has been widely used in the field of biological imaging, due to it resulting in a high sensitivity and excellent signal-to-noise ratio. Here, we report the design, synthesis, and evaluation of the first LAP-activated chemiluminescent probe for LAP detection and imaging. The probe initially had no chemiluminescence but produced an extremely strong chemiluminescence after the release of the dioxetane intermediate in the presence of LAP. The probe had high selectivity over other proteases and higher signal-to-noise ratios than commercial fluorophores. Real-time imaging results indicated that the chemiluminescence was remarkably enhanced at the mice tumor site after the probe was injected. Furthermore, the chemiluminescence of this probe in the cancerous tissues of patients was obviously improved compared to that of normal tissues. Taken together, this study has developed the first LAP-activable chemiluminescent probe, which could be potentially used in protein detection, disease diagnosis, and drug development.

Received 23rd November 2021

Accepted 17th January 2022

DOI: 10.1039/d1sc06528a

rsc.li/chemical-science

## Introduction

Cancer is a major disease that seriously endangers human health and life and causes great suffering and burden to families and society.<sup>1</sup> Therefore, early cancer detection, diagnosis, and treatment can remarkably reduce mortality and increase cure rates for patients with cancer.<sup>2</sup> Enzymes are an important class of biomarkers for tumor diagnosis and prognosis.<sup>3</sup> Certain aminopeptidases are highly expressed in many malignant tumors compared to that in normal tissue.<sup>4</sup> Leucine aminopeptidase (LAP; EC 3.4.11.1) is one of these enzymes and belongs to the M1 and M17 peptidase families as an important protein that catalyzes the hydrolysis of the N-terminal leucine residue of a protein or peptide.<sup>5</sup> LAP is overexpressed in malignant tumor cells and is involved in tumor cell proliferation, invasion, and angiogenesis (*e.g.*, HepG2 cells are LAP-overexpressed).<sup>6</sup> In medical diagnosis, LAP can be used as

a cancer-related biomarker for tumor tracking. Therefore, the development of highly sensitive and selective *in situ* detection methods that target LAP is of great importance for medical diagnosis and pathophysiology.

LAP levels can be detected *via* several methods, but the efficient tracking of LAP activity *in vitro* and *in vivo* remains a challenge. Among the methods for tracking LAP *in vivo*, *l*-leucine-*p*-nitroaniline ultraviolet detection is not suitable for real-time tracking because of its low sensitivity and poor stability.<sup>7</sup> In addition, fluorescent probes for monitoring LAP activity have greatly limited biological applications, because they present disadvantages, such as spectral crossover, autofluorescence background interference, photobleaching, and epidermal scattering under excitation by an external light source.<sup>8</sup> Therefore, chemiluminescence detection methods that can overcome these disadvantages should be developed.<sup>9</sup>

Chemiluminescence has developed into a promising sensing and imaging tool, because it does not require excitation by an external light source, is free of light scattering and autofluorescence interference, rapidly achieves extremely high signal-to-background ratios, and improves imaging sensitivity.<sup>10</sup> The phenoxy 1,2-dioxetane luminophore (Schaap's) is an excellent backbone for the construction of highly sensitive chemiluminescent probes.<sup>11</sup> Some intriguing studies have aimed to improve and extend the use of Schaap's probes for the monitoring of various chemical and biological processes. Several activable chemiluminescent probes have been developed for the detection of small molecules<sup>12</sup> (*e.g.*, H<sub>2</sub>S, H<sub>2</sub>O<sub>2</sub>, and


<sup>a</sup>Guangdong Provincial Key Laboratory of New Drug Screening, Guangzhou Key Laboratory of Drug Research for Emerging Virus Prevention and Treatment, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, Guangdong Province, People's Republic of China

<sup>b</sup>Department of Musculoskeletal Oncology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510642, Guangdong Province, People's Republic of China. E-mail: Chengk@smu.edu.cn

† Electronic supplementary information (ESI) available: Experimental details, synthesis and characterization data, and additional spectra and imaging data. See DOI: 10.1039/d1sc06528a

‡ These authors contributed equally.

Chem. Sci., 2022, 13, 2324–2330 | 2325



**Fig. 3** (A) Absorption (dashed line) and fluorescence (solid line) emission spectra of probe 1. Probe 1 (10 μM) was incubated with or without LAP (100 U L<sup>-1</sup>) in enzyme assay buffer at 37 °C for 6 h. (B) HPLC analysis of probe 1 (10 μM) before (black) and after (red) incubation with LAP (100 U L<sup>-1</sup>) in enzyme assay buffer (pH = 7.4) at 37 °C for 1 h. (C) Chemiluminescence spectra and images (inset) of probes 1 and 2 (10 μM). The probes were incubated with or without LAP (100 U L<sup>-1</sup>) at 37 °C for 10 min. (D) Chemiluminescence kinetic profiles of probes 1 and 2 (10 μM) after incubation with or without LAP (100 U L<sup>-1</sup>) at 37 °C for 6000 s. (E) Low-energy binding models of probes 1 (cyan) and 2 (green) bound to the LAP (PDB: 2hc9) interface.

The analytical conditions, including pH and temperature for the LAP assay, were studied. The hydrolysis effect of LAP on probe 1 at different temperatures was investigated. As shown in Fig. S5,<sup>†</sup> the chemiluminescence at 550 nm was remarkably enhanced as the temperature increased from 25 °C to 37 °C in the presence of LAP. The result indicated that within the experimental temperature range, probe 1 molecules have greater enzyme activity and stronger catalytic hydrolysis ability at a higher temperature. The effect of pH on the LAP activation of probe 1 was also investigated. Results showed that the maximum chemiluminescence was observed when probe 1 was incubated with LAP at pH of 6.0 to 8.0, which is close to the pH of the extracellular environment (6.5 to 7.4, Fig. S6<sup>†</sup>). Therefore, probe 1 is suitable for detecting endogenous LAP under biologically relevant conditions.

After the chemiluminescence response of probe 1 toward LAP was confirmed, the sensitivity of the probe to LAP was further determined. We compared the sensitivity of probe 1 to

that of a commercially available fluorogenic probe, Leu-AMC (the synthetic route is illustrated in Scheme S3<sup>†</sup>), which fluoresces at 450 nm after cleavage by LAP. Different LAP concentrations were used to plot the signal-to-noise (S/N) ratio against the enzyme concentration in logarithmic scale for the direct comparison of the sensitivity of probe 1 and Leu-AMC (Fig. 4A). Remarkably, probe 1 exhibited a limit of detection (LOD) of 0.008 U L<sup>-1</sup>, whereas Leu-AMC detected LAP with a LOD of 0.22 U L<sup>-1</sup> (Fig. S7<sup>†</sup>). The enhanced sensitivity of probe 1 (27.5-fold) clearly demonstrates the advantage of our chemiluminescent substrates *versus* currently existing fluorescent substrates for LAP detection assays. Additionally, the LOD of probe 1 was much lower than those of other reported fluorescent probes (Table S1<sup>†</sup>). The chemiluminescence images of probe 1 incubated with different LAP concentrations were acquired using the IVIS Lumina XR III system (Fig. 4B). The chemiluminescence images became bright as the LAP concentration increased. The S/N ratios of probe 1 and Leu-AMC after reaction with LAP for






Fig. 4 (A) S/N ratios of probe 1 and Leu-AMC against different LAP concentrations in enzyme reaction buffer (Y axis logarithmic scales). (B) Chemiluminescence images of probe 1 (10 μM) incubated with different LAP concentrations (0, 10, 20, 40, and 80 U L<sup>-1</sup>) at 37 °C for 10 min. (C) Time-course S/N ratios after probe 1 (green, 10 μM) and Leu-AMC (blue, 10 μM) were independently incubated with LAP (100 U L<sup>-1</sup>) in enzyme reaction buffer at 37 °C. Data presented are mean ± SD (*n* = 3). (D) Chemiluminescence spectra of probe 1 (10 μM) incubated with LAP (or LAP and Ube) and various potential interfering substances.

1 h were measured. Probe 1 had higher S/N ratios than Leu-AMC and achieved S/N values of approximately 1260 in less than 20 min (Fig. 4C), whereas Leu-AMC had S/N ratios consistently under 43. The superior sensitivity and high S/N ratios (more than 30-fold) of probe 1 clearly prove the advantage of the chemiluminescence modality over fluorescence modality for diagnostic assays.

The specific identification of target analyzers is one of the important indicators to evaluate the usability of probe 1. Next, the specific response of probe 1 to LAP was tested. When probe 1 (10 μM) was incubated with amino acids (*e.g.*, Hcy, L-Cys, Glu), metal ions (*e.g.*, KCl, Na<sub>2</sub>S, Al<sub>2</sub>(SO<sub>4</sub>)<sub>3</sub>) and enzymes (β-galactosidase, cathepsin B, alkaline phosphatase pyroglutamyl aminopeptidase I, LAP), only incubation with LAP resulted in chemiluminescence (Fig. 4D, S8†). Ubenimex (Ube) is a LAP inhibitor that inhibits enzyme activity by specifically binding to the Zn ion coordination catalytic center of LAP.<sup>5</sup> Ube treatment dramatically inhibited the chemiluminescence intensity, which indicates that probe 1 has specificity for LAP.

### Detection of LAP activity in living cells

Considering that probe 1 shows an ideal optical response for LAP detection *in vitro* and low toxicity to HepG2 and LO2 liver cells (Fig. S9†), probe 1 was applied to distinguish normal cells from liver cancer cells by cell imaging. HepG-2 cancer cells incubated with probe 1 showed gradually enhanced

chemiluminescence and the maximum signals were achieved at around 30 min. By contrast, the chemiluminescence was very weak over the course of incubation when cell lines were pre-treated with Ube (Fig. S10A†). Probe 1 was incubated with different amounts of LO2 and HepG2 cells for 30 min, and the chemiluminescence images in these wells were acquired (Fig. 5A). The chemiluminescence images became brighter with increasing cell number; the chemiluminescence images of HepG-2 tumor cells were much brighter than those of LO2 cells (Fig. 5B). Notably, a good linear relationship was observed between the chemiluminescence intensity and cell number from 2500 to 40 000 in the wells (Fig. S10B†). These results show that probe 1 can detect LAP activity in living cells in real time and distinguish tumor cells and normal cells through sensitive chemiluminescence imaging in different cells.

Probe 1 was incubated with LO2 cells, HepG2 cells, and HepG2 cells pretreated with Ube (40 μM) for 1 h. Results showed that the fluorescence intensity in HepG2 cells was remarkably enhanced compared to those in LO2 and Ube-pretreated HepG2 cells (Fig. 6 and S11†). Therefore, the change in fluorescence intensity is caused by endogenous LAP in cells, which indicates that LAP expression in HepG2 cells is higher than that in LO2 cells. Moreover, Ube can inhibit LAP activity in HepG2 cells and confirm the LAP-specific activation of probe 1 at the cell level.

The cell subcellular localization experiment was performed to study the location where probe 1 enters the main agglomeration of cells after enzyme activation. The experimental results






Fig. 5 (A) Chemiluminescence images of HepG2 and LO2 cells, which have different densities, after incubation with 10  $\mu\text{M}$  probe 1 (or probe 1 with Ube) at 37  $^{\circ}\text{C}$  for 30 min. (B) Quantification of (A). Data presented are mean  $\pm$  SD ( $n = 3$ ). (C) Chemiluminescence imaging of LAP in HepG2 tumor-bearing BALB/c nude mice after intratumoral injection with PBS (100  $\mu\text{L}$ ), probe 1 (100  $\mu\text{M}$ , 100  $\mu\text{L}$ ) or probe 1 with pre-injection of Ube (200  $\mu\text{M}$ , 100  $\mu\text{L}$ ) in 10 min. (D) LAP level in different tissues from BALB/c nude mice as determined using probe 1 (red) and Leu-AMC (black). Data presented are mean  $\pm$  SD ( $n = 3$ ).




Fig. 6 Confocal fluorescence (Flu) imaging of LO2 and HepG2 cells treated with probe 1 (10  $\mu\text{M}$ ) or probe 1 plus Ube (40  $\mu\text{M}$ ) for 1 h. The fluorescence was acquired at 500–650 nm upon excitation at 405 nm.

showed that in HepG2 cells, the fluorescence signal activated by probe 1 overlaps with the lysosome dye signal (Fig. S12<sup>†</sup>). This phenomenon is similar to the fluorescence distribution of fluorescence **product 6-1** directly incubated with HepG2 cells. This finding was obtained possibly because the fluorescent **product 6-1** activated by LAP has exposed hydroxyl groups and interacts with the weak acidity of lysosomes, which results in

the gathering of a large amount of hydrolyzed **product 6-1** in the lysosomes.

#### LAP detection in liver cancer model

*In vivo* real-time imaging offers a powerful tool for accurately diagnosing disease and suspicious lesions with valuable spatiotemporal precision. Current fluorescent probes for imaging LAP activity are not suitable for *in vivo* experiments, because they are disturbed by intrinsic auto-fluorescence background signals. Accordingly, considering the prominent performance of the LAP probe in cellular chemiluminescence imaging, we examined the applicability of probe 1 for the *in vivo* real-time visualization of endogenous LAP activity in HepG2 tumor-bearing mice. Chemiluminescence images were collected at different times after the *in situ* injection of PBS, probe 1, or probe 1 with Ube pre-injection. The experimental results showed that the chemiluminescence signal rapidly responded to LAP activity and reached the maximum at 10 min after probe 1 was injected into the tumor region (Fig. 5C and S13<sup>†</sup>). The region treated with Ube exhibited a low chemiluminescence signal under the same conditions. A very small amount of chemiluminescence signal was observed in the PBS control group. Therefore, probe 1 can be used for LAP imaging in living tumors and the real-time monitoring of LAP activity *in situ*.

Tissue samples from tumor-bearing mice were prepared and analyzed using probe 1 to further confirm the usability of probe 1 in complex biological systems. The results in Fig. 5D are consistent with the measurement trend of Leu-AMC. A higher chemiluminescence enhancement, which indicates a higher




Fig. 7 Chemiluminescence imaging and detection of LAP in human tissue samples. (A) Chemiluminescence images of LAP in normal and liver cancer tissues. Probe 1 was incubated with 10% tissue homogenate supernatant (diluted to 1 : 10, 1 : 20, 1 : 40, and 1 : 80 with saline) at 37 °C for 10 min. (B) LAP activity in human tissue samples was detected using probe 1 and Leu-AMC. The 10% tissue homogenate supernatant (diluted 1 : 10 with saline) was incubated with probe 1 (10 min) or Leu-AMC (30 min) at 37 °C. Chemiluminescence and fluorescence intensities were obtained with a microplate reader. Data presented are mean  $\pm$  SD ( $n = 3$ ,  $p < 0.005$ ).

LAP level, was obtained in the serum, liver, and tumor tissues than in other tissues. The results showed that probe 1 has excellent chemiluminescence performance, accuracy, and sensitivity for LAP analysis.

#### LAP detection in human tissue samples

Probe 1 was used to detect LAP in human tissue samples to determine whether it can distinguish normal tissue and liver cancer tissue. Chemiluminescence images were acquired after probe 1 was incubated with different concentrations of the supernatant (10% tissue homogenate) for 10 min at 37 °C in enzyme reaction buffer (Fig. 7). As shown in Fig. 7A, a super strong chemiluminescence signal was observed after probe 1 was incubated with the supernatant of 10% liver cancer tissue homogenate, whereas a weak chemiluminescence intensity was detected in normal tissues. LAP activity in human tissue samples (normal and liver cancer tissues) was detected using probe 1. The results are consistent with the measurement trend of Leu-AMC, which indicates that probe 1 is a reliable detection method that can be used to distinguish normal tissue and liver cancer tissue and detect LAP activity (Fig. 7B).

## Conclusions

In summary, we designed and synthesized a LAP-activable chemiluminescent probe and proved its mechanism and specificity for LAP detection. The sensitivity for LAP detection of the chemiluminescent probe was greatly improved compared with traditional fluorescent probes. Furthermore, our study shows that probe 1 can detect LAP-related cells *in vitro* and can be used to image LAP in living tumors and monitor its activity *in situ* in real time. In addition, the chemiluminescence of the probe in liver cancer tissues was remarkably enhanced compared to that in normal tissues, which enables the differentiation between liver cancer tissues and normal tissue through endogenous LAP detection. Therefore, the successful application of probe 1 makes it a valuable imaging tool for LAP-related physiological and pathological processes and medicine. We anticipate that

the design strategy proposed in this study could be broadly used for the development of other protease probes for protein detection, disease diagnosis, and drug discovery.

## Data availability

All experimental supporting data and procedures are available in the ESI.†

## Author contributions

K. C. supervised and analyzed the experiments. B.-Q. W. designed and performed the majority experiments. Z.-Z. C. and X.-H. C. contributed to the initial implementation and data analysis. Y.-Q. L., E. L., L. Z., and Y.-J. Z. guided and revised the paper. All authors have given approval to the final version of the manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

All animal studies were conducted according to institutional animal care and use regulations approved by the Animal Research Center of Southern Medical University (Permit number SCKK 2016-0041). This work was supported by grants from the National Natural Science Foundation of China (no. 81773558 and 82073689), the National Natural Science Foundation of Guangdong Province (no. 2020A151501518 and 2018B030312010), and the Science and Technology Program of Guangzhou (201904010380).

## Notes and references

- 1 H. Sung, J. Ferlay, R. L. Siegel, *et al.*, *Ca-Cancer J. Clin.*, 2021, **71**, 209–249.



- 2 F. Bray, J. Ferlay, I. Soerjomataram, *et al.*, *Ca-Cancer J. Clin.*, 2018, **68**, 394–424.
- 3 J. Zhang, X. Chai, X. P. He, *et al.*, *Chem. Soc. Rev.*, 2019, **48**, 683–722.
- 4 H. Li, Q. Yao, W. Sun, *et al.*, *J. Am. Chem. Soc.*, 2020, **142**, 6381–6389.
- 5 (a) D. Cheng, J. Peng, Y. Lv, *et al.*, *J. Am. Chem. Soc.*, 2019, **141**, 6354–6361; (b) S. Mizukami, K. Tonai, M. Kaneko, *et al.*, *J. Am. Chem. Soc.*, 2008, **130**, 14376–14377.
- 6 (a) Y. Chen, *Mater. Today Chem.*, 2020, **15**, 100216; (b) L. Liu, Y. You, K. Zhou, *et al.*, *Angew. Chem., Int. Ed.*, 2019, **58**, 14929–14934; (c) Q. Gong, W. Shi, L. Li, *et al.*, *Chem. Sci.*, 2016, **7**, 788–792; (d) X. He, L. Li, Y. Fang, *et al.*, *Chem. Sci.*, 2017, **8**, 3479–3483; (e) W. Zhang, F. Liu, C. Zhang, *et al.*, *Anal. Chem.*, 2017, **89**, 12319–12326.
- 7 T. Wang, Q. Sun, H. Xiong, *et al.*, *Sens. Actuators, B*, 2020, **321**, 128631.
- 8 (a) J. Zhang, X. Chai, X. P. He, *et al.*, *Chem. Soc. Rev.*, 2019, **48**, 683–722; (b) A. C. Sedgwick, L. Wu, H. H. Han, *et al.*, *Chem. Soc. Rev.*, 2018, **47**, 8842–8880.
- 9 N. Hananya, D. Shabat, *et al.*, *Angew. Chem., Int. Ed.*, 2017, **56**, 16454–17463.
- 10 S. Gnaim, O. Green, D. Shabat, *et al.*, *Chem. Commun.*, 2018, **54**, 2073–2085.
- 11 U. Haris, H. N. Kagalwala, Y. L. Kim, *et al.*, *Acc. Chem. Res.*, 2021, **54**, 2844–2857.
- 12 (a) N. Hananya, O. Green, R. Blau, *et al.*, *Angew. Chem., Int. Ed.*, 2017, **56**, 11793–11796; (b) P. Cheng, Q. Miao, J. Li, *et al.*, *J. Am. Chem. Soc.*, 2019, **141**, 10581–10584; (c) J. Huang, J. Li, Y. Lyu, *et al.*, *Nat. Mater.*, 2019, **18**, 1133–1143; (d) K. J. Bruemmer, O. Green, T. A. Su, *et al.*, *Angew. Chem., Int. Ed.*, 2018, **57**, 7630–7634; (e) W. An, L. S. Ryan, A. G. Reeves, *et al.*, *Angew. Chem., Int. Ed.*, 2019, **58**, 1361–1365; (f) J. Sun, Z. Hu, S. Zhang, *et al.*, *ACS Sens.*, 2019, **4**, 87–92; (g) L. S. Ryan, J. Gerberich, J. Cao, *et al.*, *ACS Sens.*, 2019, **4**, 1391–1398; (h) N. Hananya, D. Shabat, *et al.*, *ACS Cent. Sci.*, 2019, **5**, 949–959; (i) S. Ye, N. Hananya, O. Green, *et al.*, *Angew. Chem., Int. Ed.*, 2020, **59**, 14326–14330; (j) T. Eilon-Shaffer, M. Roth-Konforti, A. Eldar-Boock, *et al.*, *Org. Biomol. Chem.*, 2018, **16**, 1708–1712; (k) W. Adam, I. Bronstein, B. Edwards, *et al.*, *J. Am. Chem. Soc.*, 1996, **118**, 10400–10407; (l) T. Eilon-Shaffer, M. Roth-Konforti, A. Eldar-Boock, *et al.*, *Org. Biomol. Chem.*, 2018, **16**, 1708–1712.
- 13 (a) M. Yang, J. N. Huang, J. Fan, *et al.*, *Chem. Soc. Rev.*, 2020, **49**, 6800–6815; (b) R. An, S. Wei, Z. Huang, *et al.*, *Anal. Chem.*, 2019, **91**, 13639–13646; (c) S. Gutkin, O. Green, G. Raviv, *et al.*, *Bioconjugate Chem.*, 2020, **31**, 2488–2493; (d) A. Fu, H. Wang, T. Huo, *et al.*, *Anal. Chem.*, 2021, **93**, 6501–6507; (e) J. I. Scott, S. Gutkin, O. Green, *et al.*, *Angew. Chem., Int. Ed.*, 2021, **60**, 5573–6184; (f) O. Shelef, A. C. Sedgwick, S. Pozzi, *et al.*, *Chem. Commun.*, 2021, **57**, 11386–11389; (g) O. Shelef, A. C. Sedgwick, S. Pozzi, *et al.*, *Chem. Commun.*, 2021, **57**, 11386–11389.
- 14 M. Roth-Konforti, O. Green, M. Hupfeld, *et al.*, *Angew. Chem., Int. Ed.*, 2019, **58**, 10361–10367.
- 15 B. M. Babin, G. Fernandez-Cuervo, J. Sheng, *et al.*, *ACS Cent. Sci.*, 2021, **7**, 803–814.
- 16 (a) Y. Zhang, X. Chen, Q. Yuan, *et al.*, *Chem. Sci.*, 2021, **12**, 14855–14862; (b) Y. Liu, L. Teng, C. Xu, *et al.*, *Chem. Sci.*, 2019, **10**, 10931–10936; (c) X. Huang, Q. Lei, S. Huang, *et al.*, *Chem. Commun.*, 2021, **57**, 6608–6611.
- 17 (a) O. Green, S. Gnaim, R. Blau, *et al.*, *J. Am. Chem. Soc.*, 2017, **139**, 13243–13248; (b) Y. Zhang, C. Yan, C. Wang, *et al.*, *Angew. Chem., Int. Ed.*, 2020, **59**, 9059–9066.
- 18 (a) M. Yang, J. Zhang, D. Shabat, *et al.*, *ACS Sens.*, 2020, **5**, 3158–3164; (b) J. Huang, Y. Jiang, J. Li, *et al.*, *Angew. Chem., Int. Ed.*, 2021, **60**, 3999–4003.
- 19 (a) M. Zhang, Z. Tian, J. Wang, *et al.*, *ACS Sens.*, 2021, **6**, 3604–3610; (b) M. Sakabe, D. Asanuma, M. Kamiya, *et al.*, *J. Am. Chem. Soc.*, 2013, **135**, 409–414; (c) H. Fujioka, J. Shou, R. Kojima, *et al.*, *J. Am. Chem. Soc.*, 2020, **142**, 20701–20707.

